Benznidazole in Chagas disease study: do the data justify progression to phase 3? – Authors’ reply

Simple item page
dc.contributor.authorFaustino Torrico
dc.contributor.authorFabiana Barreira
dc.contributor.authorNathalie Strub‐Wourgaft
dc.contributor.authorIsabella Ribeiro
dc.contributor.authorSergio Sosa‐Estáni
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:15:41Z
dc.date.available2026-03-22T21:15:41Z
dc.date.issued2021
dc.descriptionCitaciones: 2
dc.identifier.doi10.1016/s1473-3099(21)00336-4
dc.identifier.urihttps://doi.org/10.1016/s1473-3099(21)00336-4
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/86889
dc.language.isoen
dc.publisherElsevier BV
dc.relation.ispartofThe Lancet Infectious Diseases
dc.sourceUniversity of San Simón
dc.subjectBenznidazole
dc.subjectDiscontinuation
dc.subjectAdverse effect
dc.subjectRegimen
dc.subjectPlacebo
dc.subjectMedicine
dc.subjectInternal medicine
dc.subjectPopulation
dc.titleBenznidazole in Chagas disease study: do the data justify progression to phase 3? – Authors’ reply
dc.typeletter

Files

Collections

Artículo Científico Publicado